Latest news for Medios (OTC:MEDOF) Stock

Medios AG is engaged as a wholesaler for pharmaceutical medicinal products. The operating segments of the company includes provision of medicinal products which focuses on pharmaceutical medicinal products; Patient-specific therapies comprise the manufacture of medications.

Medios AG

WIIM

GameStop shares are trading higher. The company reported Q3 financial results.

News

Management

MAA Names A. Bradley Hill As CEO Effective April 1, 2025, Succeeding Retiring CEO H. Eric Bolton Jr.; Bolton To Serve As Executive Chairman And Remain Chairman Of The Board

Intuitive Surgical (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ISRG#NASDAQ">ISRG</a>) has outperformed the market over the past 15 years by 8.62% on an annualized basis producing an average annual return of 20.53%. Currently, Intuitive Surgical has a market capitalization of $191.66 billion. 
Buying $1000 In ISRG: If an investor had bought $1000 of ISRG stock 15 years ago, it would be worth $16,578.15 today based on a price of $538.09 for ISRG at the time of writing.
<h3>Intuitive Surgical's Performance Over Last 15 Years</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1733866213_0.png" alt="comp_fig" />
Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Trading Ideas

ISRG

$1000 Invested In Intuitive Surgical 15 Years Ago Would Be Worth This Much Today

IBRX

ImmunityBio shares are trading lower after the company proposed a public offering of common stock.

MIND Technology (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MIND#NASDAQ">MIND</a>) reported quarterly earnings of $2.87 per share which beat the analyst consensus estimate of $0.08 by 3487.5 percent.

Earnings

Earnings Beats

MIND

MIND Technology Q3 EPS $2.87 Up From $(0.27) YoY, Sales $12.11M Beat $10.25M Estimate

Buybacks

Prudential Financial Authorizes $1B Stock Buyback Program For 2025

Offerings

ImmunityBio, Inc. Announces Proposed Public Offering of Common Stock, Size Not Announced

Kroger Co (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/KR#NYSE">KR</a>) shares are trading higher Tuesday afternoon following reports that a U.S. judge blocked the company&#8217;s proposed <a href="https://www.benzinga.com/government/24/09/40693260/kroger-albertsons-merger-in-ftc-crosshairs-customers-competitors-at-risk">merger with Albertsons Companies Inc </a>(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ACI#NYSE">ACI</a>).
What Happened: U.S. District Judge Adrienne Nelson ruled in favor of the U.S.&nbsp;Federal Trade Commission (FTC) in a decision filed in Oregon federal court on Tuesday, according to <a href="https://www.bloomberg.com/news/articles/2024-12-10/kroger-s-24-6-billion-albertsons-deal-blocked-by-federal-judge?embedded-checkout=true">Bloomberg</a>. Nelson found that the merger deal would impact competition in the grocery space.
The FTC had argued that the proposed deal violated antitrust laws. The companies submitted a plan to the FTC that included the divestiture of hundreds of stores to C&amp;S Wholesale Grocers in order to maintain appropriate competition in the space. Nelson on Tuesday found that the divestiture plans wouldn&#8217;t do enough to replace competition that would be impacted as a result of the deal.
From Last Week: <a href="https://www.benzinga.com/news/retail-sales/24/12/42257325/ai-revolutionizes-black-friday-shopping-as-online-sales-reach-new-heights">AI Revolutionizes Black Friday Shopping As Online Sales Reach New Heights</a>
Kroger would have owned approximately 5,000 stores across the U.S. if the deal was approved. Kroger and Albertsons argued at trial that the companies needed to merge to keep pace with global conglomerates like Walmart and Amazon, per Reuters. On the other hand, grocery workers&#8217; unions criticized the merger, arguing it was likely to result in job losses.
The report indicates that the ruling likely marks the end of the deal. Attorneys for both companies reportedly said the deal would most likely be squashed if the judge ruled in favor of the FTC.
Kroger shares jumped more than 5% on the news, while Albertsons shares fell close to 4%.
KR Price Action: Kroger shares are up about 32% year-to-date. The stock closed Tuesday up 5.14% at $60.73, according to data from <a href="http://pro.benzinga.com">Benzinga Pro</a>.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/analyst-ratings/analyst-color/24/12/42423745/december-interest-rate-cut-is-almost-a-done-deal-could-wednesday-inflation-data-derail-investor-hopes">December Interest Rate Cut Is Almost A Done Deal: Could Wednesday Inflation Data Derail Investor Hopes?</a></li>
</ul>
Photo: Shutterstock.

Legal

Movers

Kroger Stock Up After Judge Blocks Albertsons Deal: What You Need To Know

MIND Technology (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MIND#NASDAQ">MIND</a>) reported quarterly sales of $12.10 million which beat the analyst consensus estimate of $10.25 million by 18.05 percent. This is a 143.26 percent increase over sales of $4.97 million the same period last year.

MIND Technology Q3 Sales $12.10M Beat $10.25M Estimate

RCKT

Rocket Pharmaceuticals shares are trading lower after the company proposed a $150 offering of common stock.

SPRB

Trading Halt: Halt status updated at 4:25:00 PM ET: Quotation Resumption: News and Resumption Times

SLRN

Trading Halt: Halted at 4:25:00 p.m. ET - Trading Halt: Halt News Pending

SPWH

Sportsman's Warehouse shares are trading higher after the company reported a year-over-year increase in Q3 adjusted EPS results and issued FY24 revenue guidance above estimates.

Guidance

GE Vernova Sees 2025 Revenue Of $36B - $37B (Est $37.249B), Up From Mid-Single Digits Organic Growth (Implied $35B - $37B)

Avid Bioservices (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CDMO#NASDAQ">CDMO</a>) reported quarterly losses of $(0.27) per share which missed the analyst consensus estimate of $(0.12) by 125 percent. This is a 80 percent decrease over losses of $(0.15) per share from the same period last year. The company reported quarterly sales of $33.50 million which missed the analyst consensus estimate of $33.80 million by 0.89 percent. This is a 31.89 percent increase over sales of $25.40 million the same period last year.

Earnings Misses

CDMO

Avid Bioservices Q2 EPS $(0.27) Misses $(0.12) Estimate, Sales $33.50M Miss $33.80M Estimate

QTTB

Q32 Bio shares are trading lower after the company announced that while its SIGNAL-AD Phase 2a clinical trial in atopic dermatitis showed promising findings in Part A, it did not meet the primary endpoint in Part B.

FEIM

Frequency Electronics shares are trading higher after the company reported a year-over-year increase in Q1 financial results.

-- SIGNAL-AA demonstrated encouraging clinical activity of&nbsp;bempikibart in patients with alopecia areata (AA), including improvement from baseline on SALT score and meaningful achievement of SALT-20 response --
-- SIGNAL-AD Phase 2a clinical trial in&nbsp;atopic dermatitis demonstrated promising findings in Part A but did not meet primary endpoint in Part B --
-- Across both trials,&nbsp;bempikibart was observed to be safe and well tolerated; demonstrated potent IL-7 and TSLP inhibition via changes in both Th2 biomarkers and T-cells, and desired target engagement --
-- Based on these results, Company plans to advance&nbsp;bempikibart in patients with AA --
WALTHAM, Mass., Dec. 10, 2024 /PRNewswire/ -- Q32 Bio Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/QTTB#NASDAQ">QTTB</a>) ("Q32 Bio"), a clinical stage biotechnology company focused on developing biologic therapeutics to restore immune homeostasis, today announced topline results from the SIGNAL-AA Phase 2a signal finding clinical trial evaluating bempikibart (ADX-914), which identified encouraging clinical activity in patients with alopecia areata (AA). The Company plans to expand the SIGNAL-AA Phase 2a clinical trial and enroll additional patients evaluating bempikibart in AA.

Biotech

General

Q32 Bio Provides Bempikibart Program Update, Including Next Steps For Advancing Alopecia Areata Development Program; SIGNAL-AD Phase 2a Clinical Trial In Atopic Dermatitis Demonstrated Promising Findings In Part A But Did Not Meet Primary Endpoint In Part B; Based On These Results, Company Plans To Advance Bempikibart In Patients With AA

Eagle Materials To Acquire Bullskin Stone & Lime In Western Pennsylvania For $152.5M; Deal Expected To Close Within 60 Days Pending Closing Conditions

JOBY

Joby Aviation shares are trading lower after the company announced it entered into an equity distribution agreement for the sale of $300 million worth of common stock.

In a report released today, Alexander Galitsa from Hauck & Aufhaeuser maintained a Buy rating on Medios AG (MEDOF – Research Report), with a price ...

Medios AG (MEDOF) Gets a Buy from Hauck & Aufhaeuser

In a report released on August 13, Matthias Maenhaut from Kepler Capital maintained a Buy rating on Medios AG (MEDOF – Research Report), with a pri...

Kepler Capital  Keeps Their Buy Rating on Medios AG (MEDOF)

In a report released yesterday, Charlotte Friedrichs from Berenberg Bank maintained a Buy rating on Medios AG (MEDOF – Research Report), with a pri...

Medios AG (MEDOF) Receives a Buy from Berenberg Bank

There's a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Medios AG (MEDOF – Research Report) and Medtronic (M...

Wall Street Analysts Are Bullish on Top Healthcare Picks

Berenberg Bank analyst Charlotte Friedrichs maintained a Buy rating on Medios AG (MEDOF – Research Report) today and set a price target of €35.00. ...

Medios AG (MEDOF) Gets a Buy from Berenberg Bank

Medios AG (MEDOF) Receives a Buy from Hauck & Aufhaeuser

Analysts have been eager to weigh in on the Healthcare sector with new ratings on Medios AG (MEDOF – Research Report), Urogen Pharma (URGN – Resear...

Analysts Offer Insights on Healthcare Companies: Medios AG (OtherMEDOF), Urogen Pharma (URGN) and Siemens Healthineers AG (OtherSEMHF)

Analysts have been eager to weigh in on the Healthcare sector with new ratings on Marinus (MRNS – Research Report) and Medios AG (MEDOF – Research ...

Analysts Offer Insights on Healthcare Companies: Marinus (MRNS) and Medios AG (OtherMEDOF)

In a report released on November 12, Matthias Maenhaut from Kepler Capital maintained a Buy rating on Medios AG (MEDOF – Research Report), with a p...

Medios AG (MEDOF) Gets a Buy from Kepler Capital

Warburg Research analyst Michael Heider maintained a Buy rating on Medios AG (MEDOF – Research Report) today and set a price target of €36.00. The ...

Comments

Medios

News

Latest news for Medios (OTC:MEDOF) Stock

Popular Channels

Tools & Features

Partners & Contributors

About Benzinga